Join us at ASMS 2016 where we announce the launch of a new solution related to metabolite identification that I’m personally very excited about sharing with the scientific community. In addition to the launch of our new product, ACD/Labs will be exhibiting at booth #701, participating in a presentation, and hosting a seminar.
The R&D industry has been evolving for decades to make the process of discovering new compounds and formulations in the laboratory easier and more effective. Today, innovative trends, focused predominantly around data and technology, encourage changes that aim to improve efficiencies across the industry. A couple of current trends we’re observing include open innovation (or externalization), as well as big data.
With the help of ACD/Labs’ software, PharmaSea researchers have dereplicated more than 300 extracts, and, as a result, have identified 10 novel compounds that merit further research. Prof. Marcel Jaspars, head of the Marine Biodiscovery Centre at the University of Aberdeen, and project leader of PharmaSea, discusses the PharmaSea project in detail here.
At ACD/Labs, we have spent two decades working with customer organizations to support effective analytical data management. While we are privy to the problems of our customers, we wondered how the wider R&D community has been addressing analytical data management and what challenges remained. With that in mind, we decided to conduct a survey last year to gather feedback from scientists (62% of survey respondents), managers, directors, and executives (26%), as well as IT and other professionals (12%) to better understand the R&D landscape.
Join us at PITTCON 2016 in Atlanta, Georgia, as we participate in a number of presentations, network with our fellow scientists and discuss upcoming mixture analysis capabilities on the ACD/Spectrus Platform.
The 'Amazon Effect' describes how online shopping giant, Amazon, sorts data and matches similar products to one another—providing customers with a customized list of products they may be interested in. In laboratory informatics, scientists organize and analyze data in a very similar way. By using software like ACD/Spectrus Platform, scientists—from different laboratories using a variety of instruments—can combine and process their large data sets in a single interface that delivers quality results.
En route to SLAS 2016 in San Diego to talk about ‘Tackling Obstacles to Analytical Knowledge Externalization’ I was struck by the congruity of the breathtaking road I was taking with the topic planned for the Informatics–Data Wrangling session. National Geographic noted the road as “An exhilarating driving experience…In places, the road has narrow shoulders and sharp drop-offs, so stay alert”. The Informatics landscapes of modern science-based organizations also offer remarkable challenges to navigate.
Over the course of the last four months, we have been working with Scientific Computing to publish a series of articles on a subject that we feel very passionately about (and work very close with) at ACD/Labs – the externalization of scientific research and development (read the summary here). Essentially, we used this opportunity to address some key trends specific to this topic from various perspectives in the industry. Now that the series is complete, I wanted to give you an overview of the four articles to paint a broader picture of what we, and some of our customers and partners, are seeing today.
I’d like to take a few moments to explore one technology which is the underlying heart of our solutions for scientists involved in NMR. The algorithms of ACD/NMR Predictors are perhaps now the unsung heroes of our software. But after becoming ubiquitous in our products (and that of other companies) is there any way to estimate how useful it is to have access to accurate NMR predictions? And will the advent of quantum computing have an appreciable impact on NMR predictions and interpretation?
For those of you that know me, you may be wondering why I re-joined ACD/Labs; for those that don’t know me yet, let me give you some insight into my return. When I think back on many happy firsts in my life, and I can’t not think about my career experience at the same time. And when I began to contemplate a return to ACD/Labs, the first thing that came to my mind was, of all things, Star Wars and JJ Abrams. Let me explain...